- Home
- CGBD vs MLYS Comparison
CGBD vs MLYS Comparison
Compare CGBD & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- MLYS
- Stock Information
- Founded
- CGBD 2012
- MLYS 2019
- Country
- CGBD United States
- MLYS United States
- Employees
- CGBD N/A
- MLYS N/A
- Industry
- CGBD Finance: Consumer Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CGBD Finance
- MLYS Health Care
- Exchange
- CGBD Nasdaq
- MLYS Nasdaq
- Market Cap
- CGBD 1.0B
- MLYS 893.0M
- IPO Year
- CGBD 2017
- MLYS 2023
- Fundamental
- Price
- CGBD $13.67
- MLYS $14.65
- Analyst Decision
- CGBD Hold
- MLYS Strong Buy
- Analyst Count
- CGBD 3
- MLYS 3
- Target Price
- CGBD $14.00
- MLYS $33.00
- AVG Volume (30 Days)
- CGBD 404.4K
- MLYS 650.3K
- Earning Date
- CGBD 05-06-2025
- MLYS 05-12-2025
- Dividend Yield
- CGBD 12.94%
- MLYS N/A
- EPS Growth
- CGBD N/A
- MLYS N/A
- EPS
- CGBD 1.31
- MLYS N/A
- Revenue
- CGBD $225,447,000.00
- MLYS N/A
- Revenue This Year
- CGBD $4.34
- MLYS N/A
- Revenue Next Year
- CGBD $2.48
- MLYS N/A
- P/E Ratio
- CGBD $10.48
- MLYS N/A
- Revenue Growth
- CGBD N/A
- MLYS N/A
- 52 Week Low
- CGBD $13.12
- MLYS $8.24
- 52 Week High
- CGBD $18.74
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- CGBD 35.35
- MLYS 53.36
- Support Level
- CGBD $13.32
- MLYS $14.03
- Resistance Level
- CGBD $14.95
- MLYS $15.79
- Average True Range (ATR)
- CGBD 0.40
- MLYS 0.99
- MACD
- CGBD -0.02
- MLYS 0.10
- Stochastic Oscillator
- CGBD 19.13
- MLYS 57.57
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.